<SEC-DOCUMENT>0000905718-21-000728.txt : 20210524
<SEC-HEADER>0000905718-21-000728.hdr.sgml : 20210524
<ACCEPTANCE-DATETIME>20210524093435
ACCESSION NUMBER:		0000905718-21-000728
CONFORMED SUBMISSION TYPE:	SC 13D
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210524
DATE AS OF CHANGE:		20210524
GROUP MEMBERS:		ABINGWORTH BIOVENTURES 8 LP

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vera Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001831828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812744449
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92556
		FILM NUMBER:		21951574

	BUSINESS ADDRESS:	
		STREET 1:		170 HARBOR WAY
		STREET 2:		3RD FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-770-0077

	MAIL ADDRESS:	
		STREET 1:		170 HARBOR WAY
		STREET 2:		3RD FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abingworth LLP
		CENTRAL INDEX KEY:			0001397144
		IRS NUMBER:				980518585
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		SC 13D

	BUSINESS ADDRESS:	
		STREET 1:		38 JERMYN STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			SW1Y 6DN
		BUSINESS PHONE:		44 (0)20 7534 1500

	MAIL ADDRESS:	
		STREET 1:		38 JERMYN STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			SW1Y 6DN
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D
<SEQUENCE>1
<FILENAME>vera_13dmay182021.htm
<DESCRIPTION>SC 13D
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt/18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 12pt/18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt/18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 12pt/18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE 13D</B></P>

<P STYLE="font: 12pt/18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 12pt/18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid">Vera Therapeutics,
Inc.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name of Issuer)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid">Class A Common Stock,
par value $0.001 per share</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Title of Class of Securities)</P>

<DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 0.75pt solid">

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">92337R 101</P>

</DIV>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">(CUSIP Number)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">John Heard</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">Abingworth LLP</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">Princes House</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">38 Jermyn Street</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">London, England SW1Y 6DN</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">+44 20 7534 1500</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-top: Black 0.75pt solid">(Name, Address and
Telephone Number of Person</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">Authorized to Receive Notices and Communications)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid">May 18, 2021</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Date of Event which Requires Filing of this Statement)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the filing person has previously filed a statement
on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of <FONT STYLE="font-family: Playbill">&sect;&sect;</FONT>
240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note</B>: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See <FONT STYLE="font-family: Playbill">&sect;</FONT>
240.13d-7 for other parties to whom copies are to be sent.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">*The remainder of this cover page shall be filled
out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required on the remainder of this
cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the Securities Exchange Act of 1934 (&#8220;Act&#8221;)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">CUSIP
    No.&nbsp;&nbsp;&nbsp; 92337R 10</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">1.</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0"><FONT STYLE="font-size: 11pt">Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only):</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0 0"><FONT STYLE="font-size: 11pt">Abingworth LLP</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0 0"><FONT STYLE="font-size: 11pt">98-0518585</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-right: 5.75pt"><FONT STYLE="font-size: 11pt">2.</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Check
    the Appropriate Box if a Member of a Group (See Instructions):</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">(a)&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">(b)&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">3.</FONT></TD>
    <TD COLSPAN="6" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">SEC
    USE ONLY</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">4.</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Source of Funds (See Instructions): &nbsp;&nbsp;WC
    (See Item 3)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">5.</FONT></TD>
    <TD COLSPAN="6" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Check if
    Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">6.</FONT></TD>
    <TD COLSPAN="6" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Citizenship
    or Place of Organization:&nbsp;&nbsp;&nbsp;&nbsp;England</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="border-top: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Number of</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">7.&#9;Sole
    Voting Power:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">0&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Shares Beneficially</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">8.&#9;Shared
    Voting Power:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">2,960,231*</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Owned by</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Each Reporting</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">9.&#9;Sole
    Dispositive Power:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">0&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Person with</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">10.&#9;Shared
    Dispositive Power:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">2,960,231*</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: right; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">11.</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Aggregate
    Amount Beneficially Owned by Each Reporting Person:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: right"><FONT STYLE="font-size: 11pt">2,960,231*&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">12.</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Check if the Aggregate Amount in Row
    (11) Excludes Certain Shares (See Instructions):&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">13.</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Percent
    of Class Represented by Amount in Row (11):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.6%*</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: right"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">14.</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Type
    of Reporting Person (See Instructions):&nbsp;&nbsp;&nbsp;PN</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: right">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 29%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD></TR></TABLE>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">*As of May 18, 2021 (the &#8220;<U>Event Date</U>&#8221;),
Abingworth LLP (&#8220;<U>Abingworth LLP</U>&#8221;) may be deemed to beneficially own an aggregate of 2,960,231 shares of Class A Common
Stock, par value $0.001 per share (the &#8220;<U>Common Stock</U>&#8221;), of Vera Therapeutics, Inc. (the &#8220;<U>Issuer</U>&#8221;)
held by Abingworth Bioventures 8 LP (&#8220;<U>Abingworth 8</U>&#8221;). Excludes options to purchase up to 9,925 shares of Common Stock
issued to Kurt von Emster which vest on the earlier of May 13, 2022 or the Issuer&#8217;s 2022 annual meeting of stockholders. As a result
of the foregoing, Abingworth LLP, as the investment manager of Abingworth 8, may be deemed to beneficially own 2,960,231 shares of Common
Stock held by Abingworth 8. Thus, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth LLP may
be deemed to beneficially own 14.6% of the shares of Common Stock of the Issuer deemed issued and outstanding as of the Event Date.</P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing beneficial ownership percentage
is based upon 20,315,876 shares of Common Stock issued and outstanding as of the Event Date, based on information received from the Issuer
and other public information.</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD COLSPAN="8" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">CUSIP
                                            No.&nbsp;&nbsp;&nbsp;92337R 101</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">1.</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0"><FONT STYLE="font-size: 11pt">Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only):</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0 0"><FONT STYLE="font-size: 11pt">Abingworth Bioventures 8
        LP</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-right: 5.75pt"><FONT STYLE="font-size: 11pt">2.</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Check
    the Appropriate Box if a Member of a Group (See Instructions):</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">(a)&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">(b)&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">3.</FONT></TD>
    <TD COLSPAN="6" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">SEC
    USE ONLY</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">4.</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Source of Funds (See Instructions): &nbsp;&nbsp;WC
    (See Item 3)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">5.</FONT></TD>
    <TD COLSPAN="6" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Check if
    Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">6.</FONT></TD>
    <TD COLSPAN="6" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Citizenship
    or Place of Organization:&nbsp;&nbsp;&nbsp;&nbsp;England</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="border-top: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Number of</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">7.&#9;Sole
    Voting Power:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">0&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Shares Beneficially</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">8.&#9;Shared
    Voting Power:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">2,960,231*</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Owned by</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Each Reporting</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">9.&#9;Sole
    Dispositive Power:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">0&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">Person with</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">10.&#9;Shared
    Dispositive Power:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 11pt">2,960,231*</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-bottom: 3pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: right; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; line-height: 8pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">11.</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Aggregate
    Amount Beneficially Owned by Each Reporting Person:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: right"><FONT STYLE="font-size: 11pt">2,960,231*&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">12.</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Check if the Aggregate Amount in Row
    (11) Excludes Certain Shares (See Instructions):&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">13.</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Percent
    of Class Represented by Amount in Row (11):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.6%*</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: right"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">14.</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 11pt">Type
    of Reporting Person (See Instructions):&nbsp;&nbsp;&nbsp;PN</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: right">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-bottom: 6pt; padding-left: 5.75pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 29%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD></TR></TABLE>




<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">* As of May 18, 2021 (the &#8220;<U>Event Date</U>&#8221;),
Abingworth LLP (&#8220;<U>Abingworth LLP</U>&#8221;) may be deemed to beneficially own an aggregate of 2,960,231 shares of Class A Common
Stock, par value $0.001 per share (the &#8220;<U>Common Stock</U>&#8221;), of Vera Therapeutics, Inc. (the &#8220;<U>Issuer</U>&#8221;)
held by Abingworth Bioventures 8 LP (&#8220;<U>Abingworth 8</U>&#8221;). Excludes options to purchase up to 9,925 shares of Common Stock
issued to Kurt von Emster which vest on the earlier of May 13, 2022 or the Issuer&#8217;s 2022 annual meeting of stockholders. As a result
of the foregoing, Abingworth LLP, as the investment manager of Abingworth 8, may be deemed to beneficially own 2,960,231 shares of Common
Stock held by Abingworth 8. Thus, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth LLP may
be deemed to beneficially own 14.6% of the shares of Common Stock of the Issuer deemed issued and outstanding as of the Event Date.</P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing beneficial ownership percentage
is based upon 20,315,876 shares of Common Stock issued and outstanding as of the Event Date, based on information received from the Issuer
and other public information.</P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Item 1.&#9;<U>Security and Issuer</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">This Schedule 13D relates to the
Class A Common Stock, par value $0.001 per share (the &#8220;<U>Common Stock</U>&#8221;), of Vera Therapeutics, Inc., a Delaware corporation
(the &#8220;<U>Issuer</U>&#8221;). The principal executive offices of the Issuer are located at 170 Harbor Way, 3<SUP>rd</SUP> Floor,
South San Francisco, California 94080. Information given in response to each item shall be deemed incorporated by reference in all other
items as applicable.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item 2.</TD><TD><U>Identity and Background</U></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">This statement is being filed on
behalf of Abingworth Bioventures 8 LP (&#8220;<U>Abingworth 8</U>&#8221;), and Abingworth LLP (&#8220;<U>Abingworth LLP</U>&#8221; together
with Abingworth 8, the &#8220;<U>Reporting Persons</U>&#8221;), the investment manager of Abingworth 8.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The Common Stock is held directly
by Abingworth Bioventures 8. Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner
8 LLP, (together with Abingworth Bioventures 8 GP LP, the &quot;<U>General Partners</U>&quot;), serves as the general partner of Abingworth
Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth
General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The address of the principal business
office of each of the Reporting Persons is c/o Abingworth LLP, Princes House, 38 Jermyn Street, London, England SW1Y 6DN.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The principal business of Abingworth
8 is to invest in and assist growth-oriented businesses in the life science and biomedical industries. The principal business of Abingworth
LLP is to serve as the investment manager to certain investment funds, including Abingworth 8.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">None of the Reporting Persons, the
General Partners or any of their respective executive officers has, during the last five years, been convicted in a criminal proceeding.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">None of the Reporting Persons, the
General Partners or any of their executive officers has, during the last five years, been a party to a civil proceeding of a judicial
or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation
with respect to such laws.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Abingworth 8 is a limited partnership
organized under the laws of England. Abingworth LLP is a limited liability partnership organized under the laws of England.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item 3.</TD><TD><U>Source and Amount of Funds or Other Consideration</U></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">On May 18, 2021, the Issuer closed
an underwritten public offering (the &#8220;<U>Offering</U>&#8221; or &#8220;IPO&#8221;) of 4,350,000 shares of its Common Stock. Prior
to the Offering, in October, 2020, Abingworth 8 purchased 25,346,400 shares of Series C convertible preferred stock (the &#8220;<U>Preferred
Stock</U>&#8221;) of the Issuer for an aggregate purchase price of approximately $15 million. All outstanding shares of Preferred Stock
automatically converted into shares of Common Stock immediately upon the closing of the Issuer's Offering, for no additional consideration
on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the
Issuer on May 7, 2021). Abingworth 8 purchased the Preferred Stock with investment capital.</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">In the Offering, Abingworth 8 purchased
772,727 shares of the Issuer&#8217;s Common Stock for an aggregate purchase price of $8,499,997. Abingworth 8 purchased the Common Stock
with investment capital.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Currently, Mr. von Emster, a member
of Abingworth LLP, serves on the Board of Directors of the Issuer. On May 13, 2021, Mr. von Emster was granted an option, as director&#8217;s
compensation, to purchase up to 9,925 shares of Common Stock which vest on the earlier of May 13, 2022 or the Issuer&#8217;s 2022 annual
meeting of stockholders (the &#8220;<U>Option</U>&#8221;). Under an agreement between Mr. von Emster and Abingworth LLP, Mr. von Emster
is deemed to hold the&nbsp;Option&nbsp;and any shares of Common Stock issuable upon exercise of the&nbsp;Option&nbsp;for the benefit of
Abingworth 8, and must exercise the&nbsp;Option solely upon the direction of Abingworth LLP. Mr. von Emster, a Director of the Issuer,
is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by at least a majority vote and
no individual member has the sole control or voting power over the securities held by Abingworth 8. Each of Abingworth 8, Abingworth LLP,
the General Partners and each member of the Investment Committee disclaims beneficial ownership of the Common Stock held by Abingworth
8.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item 4.</TD><TD><U>Purpose of Transaction</U></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The Reporting Persons acquired the
securities reported herein for investment in the ordinary course of business because of their belief that the Issuer represents an attractive
investment based on the Issuer&#8217;s business prospects and strategy. The Reporting Persons reserve the right to acquire, or cause to
be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate
other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment
and trading policies of the Reporting Persons, market conditions or other factors.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Except as set forth herein, the
Reporting Persons do not have any plan or proposal that would relate to, or result in, any of the matters set forth under subsections
(a) through (j) of Item 4 of Schedule 13D. However, each of the Reporting Persons reserves the right to propose or participate in future
transactions which may result in one or more of such actions, including but not limited to, an extraordinary corporate transaction, such
as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions
which might have the effect of causing the Common Stock to become eligible for termination of registration under Section&nbsp;12(g) of
the Act. The Reporting Persons also retain the right to change their investment intent at any time, to acquire additional shares of Common
Stock or other securities of the Issuer from time to time, or to sell or otherwise dispose of all or part of the Common Stock beneficially
owned by them (or any shares of Common Stock into which such securities are converted) in any manner permitted by law. The Reporting Persons
may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item 5.</TD><TD><U>Interest in Securities of the Issuer</U></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">As of the date hereof, Abingworth
LLP as the investment manager of Abingworth 8 may be deemed to beneficially own an aggregate of 2,960,231 shares of Common Stock of the
Issuer held by Abingworth 8. This excludes options to purchase up to 9,925 shares of Common Stock issued to Mr. von Emster which vest
on the earlier of May 13, 2022 or the Issuer&#8217;s 2022 annual meeting of stockholders.</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">On May 13, 2021, Mr. von Emster,
a member of Abingworth LLP, was granted an option, as director&#8217;s compensation, to purchase up to 9,925 shares of Common Stock which
vest on the earlier of May 13, 2022 or the Issuer&#8217;s 2022 annual meeting of stockholders. Under an agreement between Mr. von Emster
and Abingworth LLP, Mr. von Emster is deemed to hold the&nbsp;Option&nbsp;and any shares of Common Stock issuable upon exercise of the&nbsp;Option&nbsp;for
the benefit of Abingworth 8, and must exercise the&nbsp;Option solely upon the direction of Abingworth LLP.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">As a result of the foregoing, Abingworth
LLP, as the investment manager of Abingworth 8, may be deemed to beneficially own 2,960,231 shares of Common Stock held by Abingworth
8. Thus, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth LLP may be deemed to beneficially
own 14.6% of the shares of Common Stock of the Issuer deemed issued and outstanding as of the Event Date.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The foregoing beneficial ownership
percentage is based upon 20,315,876 shares of Common Stock issued and outstanding as of the Event Date, based on information received
from the Issuer and other public information.</P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Except as described herein, during
the past sixty (60) days on or prior to May 18, 2021, there were no other purchases or sales of shares of Common Stock, or securities
convertible into or exchangeable for shares of Common Stock, by the Reporting Persons or any person or entity for which the Reporting
Persons possess voting or dispositive control over the securities thereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item 6.</TD><TD STYLE="text-align: justify; padding-right: 0.7in"><U>Contracts, Arrangements, Understandings or Relationships With Respect to Securities
of the Issuer</U></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The information set forth in Items
3 and 4 of this Statement is incorporated herein by reference.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Mr. von Emster, in his capacity
as a director may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant
to the Issuer&#8217;s nonemployee director compensation policy, in effect from time to time.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Registration Rights</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Pursuant to the terms of an Amended
and Restated Investors&#8217; Rights Agreement with the Issuer, dated October 29, 2020, certain holders of the Issuer&#8217;s Common Stock,
including Abingworth 8 are entitled to rights with respect to the registration of their shares of Common Stock (the &#8220;registerable
securities&#8221;) under the Securities Act of 1933, as amended. Beginning 180 days after the effective date of the registration statement
for the IPO, the holders of a majority of the then-outstanding registrable securities have demand rights to request the registration on
Form&nbsp;S-3&nbsp;of their registrable securities, provided the aggregate offering price, net of selling expenses, is at least $10&nbsp;million.
The stockholders may only require two registration statements on Form&nbsp;S-3.&nbsp;In addition, the holders of the then-outstanding
registrable securities can request that the Issuer register all or part of their shares on Form&nbsp;S-3&nbsp;if the Issuer is eligible
to file a registration statement on Form&nbsp;S-3&nbsp;and if the anticipated aggregate offering price, net of selling expenses, is at
least $3&nbsp;million. The stockholders may only require two registration statements on Form&nbsp;S-3&nbsp;in a&nbsp;12-month&nbsp;period.
If the Issuer registers any of its securities for public sale, holders of then-outstanding registrable securities or their permitted transferees
will have the right to include their registrable securities in such registration statement, subject to certain exclusions. All of these
registration rights will expire, with respect to any particular holder, three (3) years following the completion of the Issuer&#8217;s
IPO.</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The foregoing description of the
Amended and Restated Investors&#8217; Rights Agreement is a summary only and is qualified in its entirety by the actual terms of the agreement,
which is incorporated herein by reference. See Item 7 &#8220;Material to be Filed as Exhibits.&#8221;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Lock-up&nbsp;Agreement</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The Issuer, its directors and officers,
and the holders of substantially all of its outstanding securities, including Abingworth 8 entered into&nbsp;lock-up&nbsp;agreements,
pursuant to which they agreed with the underwriters that, for a period of 180 days following the date of the underwriting agreement in
connection with the IPO, subject to certain exceptions, they will not, directly or indirectly, offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise
transfer or dispose of any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for shares of Common
stock, or enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the
economic consequence of ownership of the securities, whether any such swap or transaction is to be settled by delivery of Common Stock
or other securities, in cash or otherwise.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The foregoing description of the
lockup agreements is a summary only and is qualified in its entirety by reference to the Form of&nbsp;Lock-up&nbsp;Agreement, which is
incorporated herein by reference. See Item 7 &#8220;Material to be Filed as Exhibits.&#8221;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item 7.</TD><TD STYLE="text-align: justify"><U>Material to be Filed as Exhibits</U></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The following exhibit
is incorporated into this Schedule 13D:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"></TD>
    <TD STYLE="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Exhibit 1</P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">Joint Filing Agreement, dated May 24, 2021, signed by each of the Reporting Persons in
                                                                                           order to confirm that this Schedule 13D (and any amendments hereto) are being filed on behalf of each of the Reporting Persons.</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Exhibit 2</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">Second
Amended and Restated Investors&#8217; Rights Agreement, dated October 29, 2020 (incorporated by reference to Exhibit 4.2 to the Issuer&#8217;s
Registration Statement on Form S-1 filed with the SEC on April 23, 2021).</P>
                                                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Exhibit 3</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Form of&nbsp;Lock-up&nbsp;Agreement (incorporated by
    reference to Exhibit A of Exhibit 1.1 to the Issuer&#8217;s Amendment to Registration Statement on
    Form&nbsp;S-1/A&nbsp;(Registration No.&nbsp;333-255492), filed with the SEC on May 10, 2021.</TD></TR></TABLE>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/200% Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Signature</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Dated: May 24, 2021</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 3.5in"><B>ABINGWORTH BIOVENTURES 8 LP</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 3.5in">By: Abingworth LLP, its Manager</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">By:<U>&#9;/s/ John Heard&#9;</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.25in">Name: John Heard</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.25in">Title: Authorized Signatory</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-indent: 0.5in"><B>ABINGWORTH LLP</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">By:<U>&#9;/s/ John Heard&#9;</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.25in">Name: John Heard</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.25in">Title: Authorized Signatory</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Attention: Intentional misstatements or omissions
of fact constitute Federal criminal violations (See 18 U.S.C. 1001).</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>vera_13dmay182021ex1.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 1</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JOINT FILING AGREEMENT</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Agreement will confirm the agreement by and among
the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial
ownership by the undersigned of the Common Shares of Vera Therapeutics, Inc. is being filed, and all amendments thereto will be filed,
on behalf of each of the persons and entities named below, in accordance with Rule 13d-1 under the Securities Exchange Act of 1934, as
amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Dated as of May 24, 2021</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 3.5in"><B>ABINGWORTH BIOVENTURES 8 LP</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 3.5in">By: Abingworth LLP, its Manager</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">By:<U>&#9;/s/ John Heard&#9;</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.25in">Name: John Heard</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.25in">Title: Authorized Signatory</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-indent: 0.5in"><B>ABINGWORTH LLP</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">By:<U>&#9;/s/ John Heard&#9;</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.25in">Name: John Heard</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.25in">Title: Authorized Signatory</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
